<DOC>
	<DOCNO>NCT01118871</DOCNO>
	<brief_summary>The purpose study look two different antiretroviral treatment option individual commence second antiretroviral treatment . This study ass important clinical laboratory difference two therapeutic option . Potential difference include : difference body fat distribution , lipid parameter , adherence neurocognitive ( brain ) function . This study look show difference body fat distribution two study treatment arm . Differences lipid , viral load , adherence , cardiac bone biomarkers neurocognitive function also assess . There also lumbar puncture sub study participant also take part . The total duration involvement trial 96 week ( approximately 2 year ) plus screen visit 1 - 4 week prior start study . Including visit clinic 12 occasion ( screen visit , baseline visit , week 2 , 4 , 8 , 12 , 24 , 36 , 48 , 64 , 80 96 )</brief_summary>
	<brief_title>The First Failure Study</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>HIV1 infect male females 18 year age sign informed consent currently receive stable antiretroviral regimen comprise : two license NRTIs one license NNRTI boost protease inhibitor previous protease inhibitor resistance document HIV1 genotypic resistance test failure current antiretroviral regimen due : toxicity , intolerance virological failure receive NNRTI contain regimen screen toxicity intolerance receive boostedprotease inhibitor regimen screen ( plasma HIV RNA &lt; 400 copies/mL screen ) willing modify antiretroviral therapy , accordance randomisation assignment previous exposure etravirine subject good health upon medical history , physical exam , laboratory test opinion investigator serologic evidence active HBV infection evidence negative hepatitis B surface antigen female subject heterosexually active childbearing potential ( i.e. , surgically sterile least two year post menopausal ) must practice contraception follow screen completion study : barrier contraceptive ( condom , diaphragm spermicide ) IUD Depo PLUS barrier contraceptive female subject childbearing potential must negative pregnancy test . current alcohol abuse drug dependence pregnancy active opportunistic infection significant comorbidities current prohibit concomitant medication likelihood diminish response study treatment arm , opinion investigator , base HIV genotypic resistance test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Treatment experience</keyword>
</DOC>